Vanguard (NTLA) files Schedule 13G reporting 5.03% ownership (5.95M)
Rhea-AI Filing Summary
Intellia Therapeutics Inc Schedule 13G filed by Vanguard Capital Management reports beneficial ownership of 5,945,571 shares of common stock, representing 5.03% of the class. The filing shows sole voting power for 861,466 shares and sole dispositive power for 5,945,571 shares. The filing lists CUSIP 45826J105 and is signed April 30, 2026.
Positive
- None.
Negative
- None.
Insights
Vanguard reports a passive >5% stake in Intellia (5.03%).
Schedule 13G entries like this indicate an institutional investor reporting beneficial ownership without an intent to influence control. The filing lists 5,945,571 shares and CUSIP 45826J105, with dispositive authority retained by Vanguard.
Court or proxy milestones are not shown; subsequent filings would be required to show any shift to active ownership or changes in voting arrangements.
Filing conforms to passive Schedule 13G disclosure requirements.
The document identifies the reporting entity, address, and the breakdown of voting and dispositive powers, satisfying Item 4 and Item 6 disclosure elements. Signature is provided by a named officer.
Any change in ownership or intent would require amendment or conversion to Schedule 13D per regulatory thresholds.
Key Figures
Key Terms
Schedule 13G regulatory
beneficially owned financial
sole dispositive power regulatory
CUSIP financial
AI-generated analysis. How Rhea-AI works. Not financial advice.